<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.122701.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Case Report</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Case Report: Adrenocortical carcinoma in an adult male with hypokalemic hypertensive: Report of a rare case in Nepal</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 1 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>K.C.</surname>
                        <given-names>Indu</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Alam</surname>
                        <given-names>Md Zafar</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Simkhada</surname>
                        <given-names>Nabin</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-4346-3940</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Jang Rayamajhi</surname>
                        <given-names>Rabindra</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Alam</surname>
                        <given-names>Rizwan</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-5889-7776</uri>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Endocrinology/ Internal Medicne, Nepalese Army Institute of Health and Sciences, Kathmandu, Bagmati, 44600, Nepal</aff>
                <aff id="a2">
                    <label>2</label>Internal Medicine, Nepalese Army Institute of Health and Sciences, Kathmandu, Bagmati, 44600, Nepal</aff>
                <aff id="a3">
                    <label>3</label>Medical Officer, Argakhachi Hospital, Argakhachi, Nepal</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:nabins72@gmail.com">nabins72@gmail.com</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>21</day>
                <month>6</month>
                <year>2022</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2022</year>
            </pub-date>
            <volume>11</volume>
            <elocation-id>681</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>15</day>
                    <month>6</month>
                    <year>2022</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2022 K.C. I et al.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/11-681/pdf"/>
            <abstract>
                <p>Adrenocortical carcinoma (ACC), with an incidence of 2-5 percent, is an uncommon source of unilateral adrenal mass and hyperaldosteronism. In Nepal, there is no literature on this uncommon adrenocortical cancer. A forty-year-old Nepalese army regular with resistant hypertension on various antihypertensive medicines presenting with a background of considerable weight loss decreased appetite, and repeated episodes of vomiting were described. His blood tests revealed hypokalemia and a high aldosterone/renin ratio. A tumor in the left adrenal gland was discovered during an abdominal CECT scan. He was operated on for left adrenal incidentaloma and the procedure was uneventful. We recommend clinicians suspect hyperaldosteronism in an adult with refractory hypertension and hypokalemia.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Adrenocortical carcinoma</kwd>
                <kwd>Hypokalemia</kwd>
                <kwd>Hypertension</kwd>
                <kwd>Aldosterone/Renin ratio</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>Adrenocortical Carcinoma is a cancerous tumor. In 25% of seemingly spontaneous ACC, somatic mutations in the tumor-suppressor gene TP53 are detected. The Li-Fraumeni syndrome is linked to a variety of solid organ malignancies, including ACC, and is caused by TP53 mutations in the sperm. Variations in the Wnt/-catenin system and the insulin-like growth factor 2 (IGF2) clusters are also evident in ACC; IGF2 amplification is reported in 90% of the cases.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup>
            </p>
            <p>Around 60% of ACCs seem to be adequately secretive in character to manifest as a clinical condition of hormone overabundance.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> Cushing's syndrome (45 percent) or a combination Cushing's and virilization syndrome (oversaturation of both glucocorticoids and androgens) are the most common symptoms in adults with hormone-secreting ACCs (25 percent).
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup> Cushing's syndrome, virilization, hypertension, hypokalemia, abdominal discomfort, and vomiting are examples of clinical symptoms linked with hormone imbalances. Diagnosis is done by radio-imaging (CECT abdomen and pelvis) or MRI abdomen and pelvis for the size of tumor and local invasion as well as metastasis. The size of the adrenal tumor at its widest point indicates if it is cancerous. Adenomas of the adrenal glands typically have a dimension smaller than 4 cm. When an ACC is detected, it usually has a diameter of larger than 4cm. FNAC cannot differentiate benign from malignant.</p>
            <p>We should always rule out pheochromocytoma by using serum and urinary catecholamines before surgery and biopsy. For adrenocortical cancer (ACC) stages I-III, total surgical removal is the only possible therapeutic strategy.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup>
            </p>
        </sec>
        <sec id="sec2">
            <title>Case presentation</title>
            <p>A 40-year-old serving soldier who has history of hypertension presented initially with decrease in appetite and loss of weight of around two to three kg over 30 days. He had been vomiting for two days about 3-4 episodes, non-projectile, and non-bloody. He also complained of generalized weakness which started after vomiting, however, he could walk and perform daily activities. He had a past history of hypertensive urgency with multiple hospital admissions. Fundoscopy revealed grade III hypertensive retinopathy changes.</p>
            <p>His blood pressure was 170/100 mmHg and pulse rate was 56 beats per minute and it was regular, respiratory rate was 18/min, saturation was 96% at room air. His systemic examinations were unremarkable. His initial hematological, renal, and liver function parameters were in the normal range but serum sodium was 146mmol/l and potassium was 2.0 mmol/l. His USG imaging and X-ray chest were unremarkable.</p>
            <p>He was admitted for evaluation of hypokalemia. His antihypertensive medications were optimized and started on Losartan, amlodipine, Beta-blocker, alpha-blocker, and diuretics (spironolactone). An extensive evaluation was done to find the cause of hypokalemia. His 24 hours urine analysis revealed potassium 18 meq/dl, osmolality 300 mosm/l, and sodium 54 mmol/dl. His serum calcium was 8.4 mg/dl and Phosphate 4.1mg/dl. The transtubular potassium gradient (TTKG) was 15 (which was 3.5 times normal levels). His aldosterone renin ratio was increased and urinary catecholamines levels were normal as shown in 
                <xref ref-type="table" rid="T1">Table 1</xref> and 
                <xref ref-type="table" rid="T2">Table 2</xref>.</p>
            <table-wrap id="T1" orientation="portrait" position="float">
                <label>Table 1. </label>
                <caption>
                    <title>Aldosterone renin ratio.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top"/>
                            <th align="left" colspan="1" rowspan="1" valign="top">Result</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">References</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Serum Aldosterone</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">535 ng/dl</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">Supine &lt;16 ng/dl, upright 4-31 ng/dl</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Serum Renin, direct</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">0.50 mcgU/ml</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">Supine 0.2-1.2, upright 0.5-4.0</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Aldosterone/Renin Ratio (ARR)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">1070 ng/dl/mcgU/ml</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">&lt;25</td>
                        </tr>
                    </tbody>
                </table>
                <table-wrap-foot>
                    <p>Note: Spironolactone, Beta blocker, alpha blocker were stopped 7 days before sending the sample.</p>
                </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T2" orientation="portrait" position="float">
                <label>Table 2. </label>
                <caption>
                    <title>Catecholamines.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top"/>
                            <th align="left" colspan="1" rowspan="1" valign="top">Results</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">References</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">24 hours urinary metanephrines</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">162.34 mcg/24 hrs</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">(74.0-297.0)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">24 hours urinary normetanephrines</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">349.45 mcg/24 hrs</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">(73.0-808)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Plasma metanephrines (free)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">25 ng/L</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">(7.9-88.70)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Plasma Normetanephrines (free)</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">62.2 ng/L</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">(20.10-135.40)</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">3-methoxytyramine</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">3.39 ng/L</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">(&lt;18.40)</td>
                        </tr>
                    </tbody>
                </table>
            </table-wrap>
            <p>The contrast-enhanced CT abdomen showed well defined, smooth marinated, heterogeneously enhancing mass lesion in the left adrenal gland measuring 5.1 cm &#x00d7; 5.9 cm &#x00d7; 5.7 cm with few tiny calcifications in the lesion. The coronal section of the contrast-enhanced CT abdomen is shown in 
                <xref ref-type="fig" rid="f1">Figure 1</xref> and the transverse section is shown in 
                <xref ref-type="fig" rid="f2">Figure 2</xref>. An overnight dexamethasone suppression test was done, and serum cortisol at 8 AM was 10.61 nmol/l. Color Doppler of bilateral renal arteries showed normal flow. The thyroid function test was normal. ABG showed metabolic alkalosis. Potassium was supplemented from the IV route as well as the oral route and six times hourly potassium was monitored but even after continuous supplement, there was no rise in serum potassium level. Intravenous fluid was given as &#x00bd; NS to avoid hypernatremia and serum sodium was monitored along with potassium.</p>
            <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                <label>Figure 1. </label>
                <caption>
                    <title>Coronal section of abdomen.</title>
                    <p>Arrow showing heterogeneously enhancing mass lesion of 5.1 cm &#x00d7; 5.9 cm &#x00d7; 5.7 cm with few tiny calcification in the lesion.</p>
                </caption>
                <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/134724/96877b3b-9a32-4d30-be49-7c487f531572_figure1.gif"/>
            </fig>
            <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                <label>Figure 2. </label>
                <caption>
                    <title>Transverse section of abdomen.</title>
                    <p>Arrow showing well defined, smooth marinated, heterogeneously enhancing mass lesion.</p>
                </caption>
                <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/134724/96877b3b-9a32-4d30-be49-7c487f531572_figure2.gif"/>
            </fig>
            <p>After confirming our diagnosis of left adrenal incidentaloma with hyperaldosteronism, He underwent laparoscopic unilateral adrenalectomy (left) and intraoperative and postoperative periods were uneventful. The Operated left adrenal mass is shown in 
                <xref ref-type="fig" rid="f3">Figure 3</xref>. Histopathological examination showed atypical cells showing marked pleomorphism exhibiting small cells to giant bizarre-shaped cells indicating adrenocortical carcinoma. The capsular invasion was seen. The immunohistochemistry report is shown in 
                <xref ref-type="table" rid="T3">Table 3</xref>.</p>
            <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                <label>Figure 3. </label>
                <caption>
                    <title>Operated left adrenal mass.</title>
                    <p>Showing operated left adrenal mass with capsulated, smooth surface, prominent surface vascular marking with maximum diameter of 7 cm and weight of 195 g.</p>
                </caption>
                <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/134724/96877b3b-9a32-4d30-be49-7c487f531572_figure3.gif"/>
            </fig>
            <table-wrap id="T3" orientation="portrait" position="float">
                <label>Table 3. </label>
                <caption>
                    <title>Immunohistochemistry.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">Pancytokeratin IHC</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">Focal positive in tumor cells</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Synaptophysin IHC</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">Positive in tumor cells</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Melan A</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">Positive in tumor cells</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Inhibin</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">Positive in tumor cells</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">Calretinin</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">Focal positive in tumor cells</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">KI-67</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">KI-67 nuclear labelling index is 30%</td>
                        </tr>
                    </tbody>
                </table>
            </table-wrap>
            <p>He was discharged with antihypertensive medications (calcium channel blocker and alpha-blocker), analgesics, oral antibiotics planned to tapper off antihypertensive every 2-3 weekly as there is a high chance of normalization of blood pressure.</p>
        </sec>
        <sec id="sec3" sec-type="discussion">
            <title>Discussion</title>
            <p>Adrenocortical carcinoma (ACC) is an uncommon adrenal neoplasm that is regarded as a highly malignant tumor. There are two variants of tumor functional and nonfunctional, functional variants are more common than nonfunctional. Females are generally more affected than males (3:1).
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> There are Bimodal peaks, appearing first in the forties and fifties and a second one appearing in their first decade. The prognosis for elderly men is poorer, although younger people with ACC have a better prognosis than adults. The majority of tumors are sporadic in nature.
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup>
            </p>
            <p>ACC can be functional with a sole endocrine condition like Cushing's, or it can be a mixed syndrome with virilization. Virilization is common in youngsters and is associated with a 70% likelihood of cancer. The majority of patients with ACC, particularly those with the non-functional form, have advanced illness with several abdominal or extra-abdominal metastatic masses.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> As a result, tumor diagnosis at an early clinical stage is critical for curative excision.</p>
            <p>Adrenal adenoma, Pheochromocytoma, and renal cell cancer are our differential diagnoses. The weight of the tumor distinguishes adenoma from carcinoma; if it weighs more than 95 g, it is typically malignant. Radio-imaging also distinguishes adenoma and carcinoma by the size, carcinoma is usually greater than 4 cm. The tumor in contrast-enhanced CT appeared heterogeneously enhanced mass lesion in the left adrenal gland measuring 5.1 cm &#x00d7; 5.9 cm &#x00d7; 5.7 cm with few tiny calcifications in the lesion. We have Weiss criteria for assessing the prognosis in ACC. If the mitotic figures are less than 20 per HPF, the tumor is low grade; if the mitotic figures are more than 20 per HPF, the tumor is high grade. The tumor is malignant if three of the nine criteria are met.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> We have calculated Weiss criteria which were 4 points out of a total of 9 points (Capsular infiltration, Necrosis, Clear cells &lt;25%, and Mitosis 10/50 HPF).</p>
            <p>ENSAT (European Network for the Study of Adrenal Tumors) and the TNM staging system are used for the tumor staging as shown in 
                <xref ref-type="table" rid="T4">Table 4</xref>. We classified this tumor as stage II (T1N0M0).</p>
            <table-wrap id="T4" orientation="portrait" position="float">
                <label>Table 4. </label>
                <caption>
                    <title>Tumor staging.</title>
                </caption>
                <table content-type="article-table" frame="hsides">
                    <thead>
                        <tr>
                            <th align="left" colspan="1" rowspan="1" valign="top">ENSAT Stage</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">TNM Stage</th>
                            <th align="left" colspan="1" rowspan="1" valign="top">TNM Definitions</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">I</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">T1,N0,M0</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">T1 - tumor size &#x2264;5 cm
                                <break/>N0 - no positive lymph node present
                                <break/>M0 - no distant metastases present</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">II</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">T2, N0, M0</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">T2 - tumor size &gt;5 cm
                                <break/>N0 - no positive lymph node present
                                <break/>M0 - no distant metastases present</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">III</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">T1&#x2013;T2,N1,M0
                                <break/>T3&#x2013;T4,N0&#x2013;N1,M0</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">N1 - positive lymph node(s) present
                                <break/>No - distant metastases detected
                                <break/>T3 - tumor infiltration into surrounding tissue
                                <break/>T4 - tumor invasion into adjacent organs or in vena cava or renal vein</td>
                        </tr>
                        <tr>
                            <td align="left" colspan="1" rowspan="1" valign="top">IV</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">T1&#x2013;T4,N0&#x2013;N1,M1</td>
                            <td align="left" colspan="1" rowspan="1" valign="top">M1 - distant metastases present</td>
                        </tr>
                    </tbody>
                </table>
            </table-wrap>
            <p>The most important differential diagnosis is Pheochromocytoma. A classic zellballen pattern characterized by elevated catecholamine levels in serum and urine, as well as positive for immunohistochemical markers such as chromogranin, will suggest a Pheochromocytoma. Whereas, inhibin, calretinin, and Melan-A, are positive in ACC. Cushing syndrome was ruled by a dexamethasone suppression test. Normal serum cortisol and high aldosterone level ruled out Liddle syndrome, a Syndrome of apparent mineralocorticoid excess (SAME). High serum level of renin is seen in renal artery stenosis (RAS), renin secreting tumor (RST), and malignant hypertension.</p>
        </sec>
        <sec id="sec4" sec-type="conclusion">
            <title>Conclusion</title>
            <p>We reported a very rare case of adrenocortical carcinoma in an adult who presented with hypokalemia and hypertension and he is living a disease-free postoperative period. Because their prognoses are distinct, it's critical to distinguish it from an adrenocortical adenoma with biochemical, imaging, and histological markers. The most common therapy is surgical resection.</p>
        </sec>
        <sec id="sec5">
            <title>Data availability</title>
            <p>No extra source data is necessary because all of the data that underpins the results is included in the article.</p>
        </sec>
        <sec id="sec6">
            <title>Consent</title>
            <p>The patient's written informed consent for publishing the clinical details and/or clinical photos was acquired.</p>
        </sec>
    </body>
    <back>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="book">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kasper</surname>
                            <given-names>DL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fauci</surname>
                            <given-names>AS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hauser</surname>
                            <given-names>SL</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <source>

                        <italic toggle="yes">Harrison's principles of internal medicine.</italic>
</source>
                    <publisher-loc>New York</publisher-loc>:
                    <publisher-name>McGraw Hill Education</publisher-name>;
                    <edition>19th edition.</edition>
                    <year>2015</year>.</mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ng</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Libertino</surname>
                            <given-names>JM</given-names>
                        </name>
</person-group>:
                    <article-title>Adrenocortical carcinoma: diagnosis, evaluation and treatment.</article-title>
                    <source>

                        <italic toggle="yes">J. Urol.</italic>
</source>
                    <year>2003 Jan</year>;<volume>169</volume>(<issue>1</issue>):<fpage>5</fpage>&#x2013;<lpage>11</lpage>.
                    <pub-id pub-id-type="pmid">12478091</pub-id>
                    <pub-id pub-id-type="doi">10.1097/01.ju.0000030148.59051.35</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wajchenberg</surname>
                            <given-names>BL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Albergaria Pereira</surname>
                            <given-names>MA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Medonca</surname>
                            <given-names>BB</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Adrenocortical carcinoma: clinical and laboratory observations.</article-title>
                    <source>

                        <italic toggle="yes">Cancer.</italic>
</source>
                    <year>2000 Feb 15</year>;<volume>88</volume>(<issue>4</issue>):<fpage>711</fpage>&#x2013;<lpage>736</lpage>.
                    <pub-id pub-id-type="pmid">10679640</pub-id>
                    <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(20000215)88:4&lt;711::AID-CNCR1&gt;3.0.CO;2-W</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Allolio</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hahner</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Weismann</surname>
                            <given-names>D</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Management of adrenocortical carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">Clin. Endocrinol.</italic>
</source>
                    <year>2004 Mar</year>;<volume>60</volume>(<issue>3</issue>):<fpage>273</fpage>&#x2013;<lpage>287</lpage>.
                    <pub-id pub-id-type="pmid">15008991</pub-id>
                    <pub-id pub-id-type="doi">10.1046/j.1365-2265.2003.01881.x</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Bellantone</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ferrante</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Boscherini</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma.</article-title>
                    <source>

                        <italic toggle="yes">Surgery.</italic>
</source>
                    <year>1997</year>;<volume>122</volume>:<fpage>1212</fpage>&#x2013;<lpage>1218</lpage>.
                    <pub-id pub-id-type="pmid">9426440</pub-id>
                    <pub-id pub-id-type="doi">10.1016/S0039-6060(97)90229-4</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/9426440">PubMed</ext-link>
                    <ext-link ext-link-type="uri" xlink:href="https://scholar.google.com/scholar_lookup?journal=Surgery&amp;title=Role+of+reoperation+in+recurrence+of+adrenal+cortical+carcinoma:+Results+from+188+cases+collected+in+the+Italian+National+Registry+for+Adrenal+Cortical+Carcinoma&amp;author=R+Bellantone&amp;author=A+Ferrante&amp;author=M+Boscherini&amp;author=CP+Lombardi&amp;author=P+Crucitti&amp;volume=122&amp;publication_year=1997&amp;pages=1212-8&amp;pmid=9426440&amp;">Google Scholar</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kock</surname>
                            <given-names>CA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Paka</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Chrousos</surname>
                            <given-names>GP</given-names>
                        </name>
</person-group>:
                    <article-title>Molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Endocrinol. Metab.</italic>
</source>
                    <year>2002</year>;<volume>87</volume>:<fpage>5367</fpage>&#x2013;<lpage>5384</lpage>.
                    <pub-id pub-id-type="doi">10.1210/jc.2002-021069</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/12466322">PubMed</ext-link>
                    <ext-link ext-link-type="uri" xlink:href="https://scholar.google.com/scholar_lookup?journal=JClinEndocrinolMetab&amp;title=Molecular+pathogenesis+of+hereditary+and+sporadic+adrenocortical+and+adrenomedullary+tumors&amp;author=CA+Kock&amp;author=K+Paka&amp;author=GP+Chrousos&amp;volume=87&amp;publication_year=2002&amp;pages=5367-84&amp;">Google Scholar</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Latronico</surname>
                            <given-names>AC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pinto</surname>
                            <given-names>EM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Domenice</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>An inherited mutation outside the highly DNA-binding domain of the P53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors.</article-title>
                    <source>

                        <italic toggle="yes">J. Clin. Endocrinol. Metab.</italic>
</source>
                    <year>2001</year>;<volume>86</volume>:<fpage>4970</fpage>&#x2013;<lpage>4973</lpage>.
                    <pub-id pub-id-type="pmid">11600572</pub-id>
                    <pub-id pub-id-type="doi">10.1210/jcem.86.10.7957</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/11600572">PubMed</ext-link>
                    <ext-link ext-link-type="uri" xlink:href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Endocrinol+Metab&amp;title=An+inherited+mutation+outside+the+highly+DNA-binding+domain+of+the+P53+tumor+suppressor+protein+in+children+and+adults+with+sporadic+adrenocortical+tumors&amp;author=AC+Latronico&amp;author=EM+Pinto&amp;author=S+Domenice&amp;author=MC+Fragoso&amp;author=RM+Martin&amp;volume=86&amp;publication_year=2001&amp;pages=4970-3&amp;pmid=11600572&amp;">Google Scholar</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jain</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kapoor</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mishra</surname>
                            <given-names>A</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Weiss criteria in large adrenocortical tumors: A validation study.</article-title>
                    <source>

                        <italic toggle="yes">Indian J. Pathol. Microbiol.</italic>
</source>
                    <year>2010</year>;<volume>53</volume>:<fpage>222</fpage>&#x2013;<lpage>226</lpage>.
                    <pub-id pub-id-type="pmid">20551521</pub-id>
                    <pub-id pub-id-type="doi">10.4103/0377-4929.64325</pub-id>
                    <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/20551521">PubMed</ext-link>
                    <ext-link ext-link-type="uri" xlink:href="https://scholar.google.com/scholar_lookup?journal=Indian+J+Pathol+Microbiol&amp;title=Weiss+criteria+in+large+adrenocortical+tumors:+A+validation+study&amp;author=M+Jain&amp;author=S+Kapoor&amp;author=A+Mishra&amp;author=S+Gupta&amp;author=A+Agarwal&amp;volume=53&amp;publication_year=2010&amp;pages=222-6&amp;pmid=20551521&amp;">Google Scholar</ext-link>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report164069">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.134724.r164069</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Ganti</surname>
                        <given-names>Apar Kishor</given-names>
                    </name>
                    <xref ref-type="aff" rid="r164069a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-3724-2671</uri>
                </contrib>
                <aff id="r164069a1">
                    <label>1</label>University of Nebraska, Nebraska, USA</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>6</day>
                <month>3</month>
                <year>2023</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Ganti AK</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport164069" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.122701.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This is a well written case report of a case of adrenal cortical carcinoma.&#x00a0;</p>
            <p> </p>
            <p> Comments:&#x00a0; 
                <list list-type="order">
                    <list-item>
                        <p>Table 4 does not add much to the article and may be omitted.</p>
                    </list-item>
                    <list-item>
                        <p>It would be helpful if the authors presented the histopathology of the resected specimen as a figure.</p>
                    </list-item>
                    <list-item>
                        <p>The discussion can be enhanced by a discussion of the management of adrenocortical carcinoma.</p>
                    </list-item>
                </list>
            </p>
            <p>Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?</p>
            <p>Yes</p>
            <p>Is the case presented with sufficient detail to be useful for other practitioners?</p>
            <p>Yes</p>
            <p>Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?</p>
            <p>Yes</p>
            <p>Is the background of the case&#x2019;s history and progression described in sufficient detail?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Medical oncology</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
</article>
